Back to top

Is Pfizer (PFE) Outperforming Other Medical Stocks This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of Pfizer (PFE - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of PFE and the rest of the Medical group's stocks.

Pfizer is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. PFE is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for PFE's full-year earnings has moved 0.09% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Our latest available data shows that PFE has returned about 2.73% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 1.84% on average. This means that Pfizer is outperforming the sector as a whole this year.

Looking more specifically, PFE belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual stocks and currently sits at #197 in the Zacks Industry Rank. On average, this group has lost an average of 0.46% so far this year, meaning that PFE is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track PFE. The stock will be looking to continue its solid performance.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Pfizer Inc. (PFE) - free report >>

More from Zacks Tale of the Tape

You May Like